Brand-Backed Body Bemoans British Columbia’s Biosimilars Boost

A body supported by biologic originators has attacked British Columbia’s move to switch Crohn’s and colitis patient to infliximab biosimilars, even though the resulting savings will be invested in patient care.

Parliament_Building_Canada
British Columbia's government has come under attack from originator-backed lobbyists over pro-biosimilar policies • Source: Shutterstock

More from Biosimilars

More from Products